Novartis agreed to buy biotechnology company Avidity in a deal valued at $12 billion, making it the Swiss drugmaker’s biggest acquisition in more than a decade and adding several potential blockbuster treatments as generic competition looms for its current top-sellers. Sam Fazeli of Bloomberg Intelligence has more. -------- More on Bloomberg Television and Markets Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance: https://tinyurl.